Skip to main content
Clinical Trials/NCT04992494
NCT04992494
Completed
Phase 2

Treatment for Migraine and Mood (Team-M): A Pilot Trial of a Mindfulness-based Training Program

NYU Langone Health1 site in 1 country27 target enrollmentNovember 11, 2021

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Migraine
Sponsor
NYU Langone Health
Enrollment
27
Locations
1
Primary Endpoint
Homework Assignment Completion Rate
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The researchers propose a two-arm pilot study of telephone and video delivered Mindfulness-based Cognitive Therapy (MBCT-T and MBCT-V) in people with migraine and depressive symptoms.

Detailed Description

This study aims to set the stage for a future definitive large-scale Phase III trial in patients with migraine and depressive symptoms. This first phase is aimed at fidelity optimization of MBCT-T and MBCT-V in people with migraine (defined by the International Classification of Headache Disorders - 3) and depressive symptoms (defined by empirical cut-offs on the Patient Health Questionnaire - 9).

Registry
clinicaltrials.gov
Start Date
November 11, 2021
End Date
June 13, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Currently meets ICHD-3 criteria for migraine using the Structured Diagnostic Interview for Headache
  • Self-reported 4-14 headache days per month, with at least one attack meeting migraine criteria
  • Score between 5-14 on the PHQ-9
  • Ability to read and speak English
  • Capacity to consent

Exclusion Criteria

  • Meeting ICHD-3 criteria for persistent headache attributed to traumatic injury to the head (post-traumatic headache) on the Structure Diagnostic Interview for Headache
  • Changes in preventive migraine medication or anti-depressant medication within 6 weeks of intake; changes in longer-term migraine prevention (onobotulinum toxin A, anti-calcitonin gene related peptide treatment) within 3 months of intake
  • Comorbid psychiatric illness or clinical features that would interfere with participant's ability to participate in or receive benefit from the MBCT intervention, including but not limited to: active suicidal ideation; recent history of psychosis or mania; borderline, histrionic or narcissistic personality disorder; cognitive impairment; sensory disabilities
  • Prior history of engaging in formal mindfulness-based interventions including: MBSR, MBCT, Acceptance and Commitment therapy, Dialectical Behavior Therapy
  • Current meditation practice \>3x/week

Outcomes

Primary Outcomes

Homework Assignment Completion Rate

Time Frame: Week 8

Defined as the proportion of assigned home-based practice that participants completed each week.

Treatment Session Adherence Rate

Time Frame: Week 8

Treatment Session Adherence is a measure of treatment feasibility and is defined as the number of scheduled treatments that were attended by the participants. This measure will be assessed through electronic monitoring of the attendance logs of each treatment session. A treatment arm will be considered feasible if participants attended/read 75% of sessions on average.

Average Client Satisfaction Questionnaire Score (CSQ-8)

Time Frame: Week 8

The CSQ-8 is an 8-item generic standardized self-report tool to measure satisfaction with health and human services received by individuals and families. An overall score is calculated by summing the respondent's rating (item rating) score for each scale item. For the CSQ-8 version, scores range from 8 to 32, with higher values indicating higher satisfaction. A threshold score of greater than or equal to 24 is the cut-off for "Acceptability."

Mean Score on MBCT-T/V Adherence & Competence Scales (MBCT-TACS)

Time Frame: Week 8

The mindfulness-based cognitive therapy (MBCT)-TACS is an assessment of treatment fidelity in terms of adherence and competence. The scores per session are recorded between 0-3 and averaged to get the total score. The total range of score is 0-3; the higher the score, the higher the fidelity.

Study Sites (1)

Loading locations...

Similar Trials